IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
Ocular pain is a $10+ billion global market with significant unmet medical need. IACTA and Pharmaleads are teaming up to accelerate global development of DENKIs, leveraging expertise and resources of both companies.
By Jessie Yount - Featured on ocbj.com CLINICAL TRIALS IACTA Pharmaceuticals Inc. in Irvine nabbed a licensing agreement with Zhaoke Ophthamology Pharmaceutical to co-develop and commercialize two drug candidates in China
By David Ho and Elise Mak - Featured on BioWorld.com HONG KONG - California-based Iacta Pharmaceuticals Inc. and Hong Kong-based Zhaoke Ophthalmology Pharmaceutical Ltd. have inked a definitive license agreement for
IRVINE, Calif. and HONG KONG -- IACTA Pharmaceuticals, Inc. ("IACTA" or the "Company") and Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited ("ZKO"), a leading Hong Kong-based pharmaceutical company, today announces they